Teva's Finasteride ANDA076511 Receives Abbreviated Approval from FDA
Teva's ANDA076511 for Finasteride has received an Abbreviated Approval from the FDA.
Published: July 9, 2026
Updated: July 9, 2026
Author: Humanexa Intelligence
Therapeutic area: Urology / 5-alpha reductase inhibitor
Company: Teva
Asset: Finasteride
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Teva
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Teva's Abbreviated Approval for Finasteride introduces a generic competitor to the market, which could significantly impact pricing and market share dynamics. Pharma strategy teams must evaluate the implications for their branded products and adjust strategies accordingly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry date and any potential challenges from branded competitors.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.